Inozyme Pharma, Inc. (INZY) Debt-to-equity % [USD] 2021 - 2024

Historical data

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Inozyme Pharma, Inc. quarterly Debt-to-equity history and growth rate from 2021 to 2024.
Inozyme Pharma, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 39.9 %, a 121% increase year-over-year.

Debt-to-equity, Quarterly (% [USD])

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q1 2024	39.9	+21.8	+121%	Mar 31, 2024
Q4 2023	37.2	+23.6	+174%	Dec 31, 2023
Q3 2023	30.8	+18.3	+146%	Sep 30, 2023
Q2 2023	26.8	+15.6	+140%	Jun 30, 2023
Q1 2023	18.1	+7.21	+66.5%	Mar 31, 2023
Q4 2022	13.6	+4.79	+54.3%	Dec 31, 2022
Q3 2022	12.5	+4.98	+66.1%	Sep 30, 2022
Q2 2022	11.2	+4.28	+62%	Jun 30, 2022
Q1 2022	10.9	+1.59	+17.2%	Mar 31, 2022
Q4 2021	8.82			Dec 31, 2021
Q3 2021	7.54			Sep 30, 2021
Q2 2021	6.91			Jun 30, 2021
Q1 2021	9.26			Mar 31, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.